Ranibizumab in Neovascular Age-related Macular Degeneration

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2007 Dec 1

PMID 18046922

Citations 11

Authors

T Eng Kenneth

Peter J Kertes

Affiliations

Soon will be listed here.

Abstract

Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.

Citing Articles

Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.

Ciftci F, Ozarslan A, Kantarci I, Yelkenci A, Tavukcuoglu O, Ghorbanpour M Pharmaceutics. 2025; 17(1).

PMID: 39861768 PMC: 11769154. DOI: 10.3390/pharmaceutics17010121.

Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.

Ghosh A, Nikumbh U, Shukla C, Laul R, Dixit A, Mahapatra S Ophthalmol Ther. 2024; 13(5):1369-1382.

PMID: 38530568 PMC: 11039601. DOI: 10.1007/s40123-024-00883-5.

Serum adropin level in wet-type age-related macular degeneration.

Saeedi-Maleki Z, Javadzadeh A, Brumandpur F, Ghorbanihaghjo A, Khanzadeh S, Mousavi F Int J Retina Vitreous. 2024; 10(1):27.

PMID: 38475838 PMC: 10935851. DOI: 10.1186/s40942-024-00543-7.

Analyzing shifts in age-related macular degeneration research trends since 2014: A bibliometric study with triple-map Sankey diagrams (TMSD).

Lin H, Chou W, Chien T, Yeh Y, Kuo S, Hsu S Medicine (Baltimore). 2024; 103(3):e36547.

PMID: 38241545 PMC: 10798733. DOI: 10.1097/MD.0000000000036547.

Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis.

Jiang S, Li X, Fu M, Huanglu D, Huang J, Huang W Int J Clin Pharm. 2023; 45(6):1317-1325.

PMID: 37204617 DOI: 10.1007/s11096-023-01584-y.

References

. Comparison of 2D reconstructions of surgically excised subfoveal choroidal neovascularization with fluorescein angiographic features: SST report No. 15. Ophthalmology. 2006; 113(2):279.e1-279.e5. DOI: 10.1016/j.ophtha.2005.10.031. View

McColm J, Geisen P, Hartnett M . VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis. 2004; 10:512-20. PMC: 1828041. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Maturi R, Bleau L, Wilson D . Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26(3):270-4. DOI: 10.1097/00006982-200603000-00003. View

Michels S, Rosenfeld P, Puliafito C, Marcus E, Venkatraman A . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005; 112(6):1035-47. DOI: 10.1016/j.ophtha.2005.02.007. View

Penfold P, Wen L, Madigan M, Gillies M, King N, Provis J . Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000; 121(3):458-65. PMC: 1905725. DOI: 10.1046/j.1365-2249.2000.01316.x. View

Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V . Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46(2):726-33. DOI: 10.1167/iovs.04-0601. View

Yang J, Haworth L, Sherry R, Hwu P, Schwartzentruber D, Topalian S . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-34. PMC: 2275324. DOI: 10.1056/NEJMoa021491. View

Smithen L, Ober M, Maranan L, Spaide R . Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004; 138(5):740-3. DOI: 10.1016/j.ajo.2004.06.067. View

10.

Larsson A, Skoldenberg E, Ericson H . Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis. 2003; 5(1-2):107-10. DOI: 10.1023/a:1021588227705. View

11.

Blinder K, Bradley S, Bressler N, Bressler S, Donati G, Hao Y . Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003; 136(3):407-18. DOI: 10.1016/s0002-9394(03)00223-x. View

12.

Gragoudas E, Adamis A, Cunningham Jr E, Feinsod M, Guyer D . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27):2805-16. DOI: 10.1056/NEJMoa042760. View

13.

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

14.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

15.

Husain D, Kim I, Gauthier D, Lane A, Tsilimbaris M, Ezra E . Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol. 2005; 123(4):509-16. DOI: 10.1001/archopht.123.4.509. View

16.

Krzystolik M, Afshari M, Adamis A, Gaudreault J, Gragoudas E, Michaud N . Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002; 120(3):338-46. DOI: 10.1001/archopht.120.3.338. View

17.

Rosenfeld P, Fung A, Puliafito C . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005; 36(4):336-9. View

18.

Spaide R, Fisher Y . Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26(3):275-8. DOI: 10.1097/00006982-200603000-00004. View

19.

Hawkins B, Bressler N, Miskala P, Bressler S, Holekamp N, Marsh M . Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology. 2004; 111(11):1967-80. PMC: 1256024. DOI: 10.1016/j.ophtha.2004.07.021. View

20.

Mordenti J, Cuthbertson R, Ferrara N, Thomsen K, Berleau L, LICKO V . Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999; 27(5):536-44. DOI: 10.1177/019262339902700507. View